Selectis Health (GBCS) Cash & Equivalents (2010 - 2025)

Selectis Health has disclosed Cash & Equivalents across 16 years of filings, most recently posting $1.0 million for Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $1.0 million, up 48.7% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.0 million (up 48.7% YoY), and the FY2025 annual result was $1.0 million, up 48.7% from the prior year.
• Cash & Equivalents came in at $1.0 million for Q4 2025 at Selectis Health, up from $417125.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $3.1 million in Q3 2023 to a low of $410866.0 in Q1 2021.
• The 5-year median for Cash & Equivalents is $834955.0 (2022), against an average of $1.0 million.
• Across the five-year window, Cash & Equivalents tumbled 80.95% in 2021 and soared 269.3% in 2023, its largest moves.
• Selectis Health's Cash & Equivalents stood at $853656.0 in 2021, then surged by 183.09% to $2.4 million in 2022, then sank by 38.57% to $1.5 million in 2023, then tumbled by 54.17% to $680332.0 in 2024, then soared by 48.7% to $1.0 million in 2025.
• The last three Cash & Equivalents figures came in at $1.0 million (Q4 2025), $417125.0 (Q3 2025), and $559983.0 (Q2 2025), per Business Quant data.